Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage Over Cisplatin and Carboplatin - YU, JING JIE; HOGAN, THOMAS; MORLEY, CHAD; CRIGGER, CHAD; JIAO, SHUNCHANG; WILLIAMS, DORIAN J.; SALKINI, MOHAMAD W.; YANG, XUQING; LIANG, XIAOBING; YAN, BINGXUE; CECIL, COURTNEY; WINN, AVA C.; et al. (Anticancer research, 2019)
Keywords: Animals; Antibodies; Apoptosis; Biocompatibility; Bone marrow; Bone Marrow - drug effects; Bone Marrow - pathology; Cancer; Cancer therapies; Carboplatin; Carboplatin - administration & dosage; Carboplatin - adverse effects; Cells; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Clinical trials; Cystoscopy; Disease Models, Animal; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Drugs; FDA approval; Female; Flow cytometry; Glutamates - administration & dosage; Glutamates - adverse effects; Humans; Immune status; Immunoblotting; In vivo methods and tests; Laboratory animals; Medical research; Mice; Molecular weight; Myelosuppression; Neoplasms - drug therapy; Neurotoxicity; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Ovaries; Proteins; Remission; Side effects; Spleen; Spleen - drug effects; Spleen - pathology; Surveillance; Testicular cancer; Beijing China; St Louis Missouri; United States--US; China; therapeutic advance; Chemotherapy; dicycloplatin (DCP); tolerable side effects